These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9458463)
21. Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Krysiak R; Gdula-Dymek A; Okopień B Pharmacol Rep; 2010; 62(6):1090-8. PubMed ID: 21273666 [TBL] [Abstract][Full Text] [Related]
22. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC; Faulds D Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964 [TBL] [Abstract][Full Text] [Related]
23. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Worz CR; Bottorff M Expert Opin Pharmacother; 2001 Jul; 2(7):1119-27. PubMed ID: 11583063 [TBL] [Abstract][Full Text] [Related]
24. Antifungal activity of statins against Aspergillus species. Qiao J; Kontoyiannis DP; Wan Z; Li R; Liu W Med Mycol; 2007 Nov; 45(7):589-93. PubMed ID: 18033614 [TBL] [Abstract][Full Text] [Related]
25. Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf. Koh KK; Oh PC; Sakuma I Int J Cardiol; 2016 Jan; 202():154-5. PubMed ID: 26397402 [No Abstract] [Full Text] [Related]
26. [Statins have other beneficial properties besides their cholesterol lowering effect]. Eriksson M Lakartidningen; 1998 Aug; 95(35):3670-2. PubMed ID: 9748780 [TBL] [Abstract][Full Text] [Related]
27. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998 [TBL] [Abstract][Full Text] [Related]
28. The Anti-hyperlipidemia Effects of Raw Polygonum multiflorum Extract in Vivo. Xian Z; Liu Y; Xu W; Duan F; Guo Z; Xiao H Biol Pharm Bull; 2017; 40(11):1839-1845. PubMed ID: 29093330 [TBL] [Abstract][Full Text] [Related]
29. Implications of 4S evidence on baseline lipid levels. Jacobson TA Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245 [No Abstract] [Full Text] [Related]
30. [Atherosclerosis in light of the evidence from large statin trials]. Cortese C; Bernardini S; Motti C Ann Ital Med Int; 2000; 15(1):103-7. PubMed ID: 10842899 [TBL] [Abstract][Full Text] [Related]
31. Statin drugs and the risk of fracture. El-Sohemy A JAMA; 2000 Oct; 284(15):1921-2. PubMed ID: 11035877 [No Abstract] [Full Text] [Related]
34. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504 [TBL] [Abstract][Full Text] [Related]
35. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence. Wong MC; Wang HH; Liu KS Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540 [No Abstract] [Full Text] [Related]
36. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs. Jankowski P; Kawecka-Jaszcz K Atherosclerosis; 2004 Jan; 172(1):191-4. PubMed ID: 14709376 [No Abstract] [Full Text] [Related]
37. [The mechanism of action of hypolipidemic drugs]. Scheen AJ Rev Med Liege; 1997 Jun; 52(6):445-6. PubMed ID: 9289779 [No Abstract] [Full Text] [Related]
38. [Pharmacology of HMG CoA reductase inhibitors (statins)]. Kostner GM Wien Med Wochenschr; 1999; 149(5-6):120-4. PubMed ID: 10408002 [TBL] [Abstract][Full Text] [Related]
39. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Wiesbauer F; Kaun C; Zorn G; Maurer G; Huber K; Wojta J Br J Pharmacol; 2002 Jan; 135(1):284-92. PubMed ID: 11786505 [TBL] [Abstract][Full Text] [Related]
40. New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines. Shrank WH; Barlow JF; Brennan TA JAMA; 2015 Oct; 314(14):1443-4. PubMed ID: 26258765 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]